BH3:FRA
PTC Therapeutics, Inc.
55,00 €
arrow_downward
-0,61%(-0,34) 1K
9-okt, 8:05:36 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoBH3 tikeri uchun statistika yaratilmoqda...
Ochish
55,00 €
Yuqori
55,00 €
Past
55,00 €
Bozor kapitali
5,30 mlrd
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
77,02 €
52 haftalik eng past
52,50 €
Xodimlar soni
991
Ochish
55,00 €
Yuqori
55,00 €
Past
55,00 €
Bozor kapitali
5,30 mlrd
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
77,02 €
52 haftalik eng past
52,50 €
Xodimlar soni
991
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance
·
1 kun oldin
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
Investing.com
·
2 kun oldin
RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform
AD HOC NEWS
·
2 kun oldin
Cantor raises target for PTC Therapeutics stock to USD 137.00
Profil
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
PTC Therapeutics, Inc. haqida
CEOMatthew B. Klein
Xodimlar soni991
Asos solingan1-yan, 1998
Bosh ofislarWarren, N'yu-Jersi, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytptcbio.com